| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2018: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
In this study, we clarify that the patients with CC genotype of STAT3 single nucleotide polymorphism (SNP) rs4796793 have a higher risk of interstitial lung disease induced by mammalian target of rapamycin (mTOR) inhibitor. Moreover, we observed that expression or activity of EMT marker and EMT related signal transduction factor is different from genotype of rs4796793 in human lung cancer cell lines.
Our study suggest that mechanism of molecular targeted drugs-induced interstitial lung disease associate with STAT3. To acumulate the data by further experiments, it is expected that STAT3 polymorphism use as the prediction marker of interstitial lung disease.
|
